TissueGen® Inc. is a developer of cutting-edge absorbable polymer technology for implantable drug delivery. The company’s unique technology enables fiber extrusion at room temperature with drugs and therapeutic agents previously impossible to incorporate in implant devices. In more ways than ever, device developers can now take advantage of drug delivery through TissueGen’s ELUTE® biodegradable drug-loaded fiber—an incredible breakthrough that drastically expands the variety of biologics to be delivered via implant.
For the first time, device developers can take advantage of the sophisticated drug delivery capabilities of absorbable fibers incorporating high levels of manufacturing tolerance to provide precise release kinetics for in vivo support and regeneration applications with a single polymer structure. TissueGen’s drug delivery technology enables the incorporation and elution of a broad range of therapeutics, including:
- protein class biologics, e.g. growth factors, enzymes, etc.;
- peptides and oligonucleotides (even viruses); and
- standard pharmaceuticals,
all in hydrophobic polymeric fibers or tubes for timed therapeutic release. Today, the TissueGen technology is used in applications in regenerative medicine and devices such as cardiac stents, peripheral vascular stents, peripheral nerve regeneration, and much more.
Built on more than four decades of experience in extruding biodegradable polymer fibers with broad drug delivery capabilities, TissueGen was founded in 2000 and currently holds a robust portfolio of issued patents on unique drug delivery technology.